MedTrace Logo

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DR-0201 in Healthy Adult Volunteers

NCT06008652 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-08-13

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, PK, PD, and immunogenicity of IV administered DR-0201 in healthy volunteers.

Conditions

  • Healthy Adult Volunteers

Interventions

DRUG

DR-0201

DR-0201 is a bi-specific antibody

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Novotech

    collaborator UNKNOWN

  • Dren Bio

    lead INDUSTRY

Principal Investigators

  • Matthias Will, MD · Dren Bio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-26
Primary Completion
2024-07-24
Completion
2024-07-24

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06008652 on ClinicalTrials.gov